Concepedia

Author

Chuke Nwachuku

National Heart Lung and Blood Institute

Also Known As

C NWACHUKU, C. Nwachuku, Chuke E Nwachuku, Chuke E. Nwachuku, Chuke Nwachuku, Nwachuku C, Strouse, John J.

25

Publications

2K

Citations

13

H-Index

29

Concepts

All Affiliations

National Heart Lung and Blood InstituteThe University of Texas Health Science Center at HoustonUniversity of WashingtonMemphis VA Medical CenterCase Western Reserve University
CN

About

Chuke Nwachuku is an author at National Heart Lung and Blood Institute specializing in cardiovascular disease, hypertension, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

504

2

Public Health

5

5

444

3

Diabetes

2

2

44

4

Epidemiology

2

2

67

5

Emergency Medicine

1

1

69

Chuke Nwachuku

×

12

Publications

2K

Citations

12

H-Index

YearCitations

Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

William C. Cushman, Charles E. Ford, Jeffrey A. Cutler,

Journal of Clinical Hypertension

2002

981

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Jackson T. Wright, William C. Cushman, Barry R. Davis,

Controlled Clinical Trials

2001

311

Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Frans H. H. Leenen, Chuke Nwachuku, Henry R. Black,

Hypertension

2006

169

Metabolic and Clinical Outcomes in Nondiabetic Individuals With the Metabolic Syndrome Assigned to Chlorthalidone, Amlodipine, or Lisinopril as Initial Treatment for Hypertension

Henry R. Black, Barry R. Davis, Joshua I. Barzilay,

Diabetes Care

2008

116

Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial

Frans L. Moll, Iris Baumgärtner, Michael R. Jaff,

Journal of Endovascular Therapy

2018

95

A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease

Ted Wun, Denis Soulières, Andrew L. Frelinger,

Journal of Hematology & Oncology

2013

70

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis

Paula T. Einhorn, Barry R. Davis, Barry M. Massie,

American Heart Journal

2006

69

Incidence and Predictors of Angioedema in Elderly Hypertensive Patients at High Risk for Cardiovascular Disease: A Report From the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Linda B. Piller, Charles E. Ford, Barry R. Davis,

Journal of Clinical Hypertension

2006

52

Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Paul A. Heidenreich, Barry R. Davis, Jeffrey A. Cutler,

Journal of General Internal Medicine

2008

37

Health-Related Quality of Life and Cost-Effectiveness Components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Rationale and Design

Mark D. Sullivan, Roger T. Anderson, David C. Aron,

The American Journal of Cardiology

2007

29

Page 1